Histigo 16 Tablet contains Betahistine 16 mg, a histamine analog used primarily in the management of vertigo associated with Ménière’s disease and other vestibular disorders. Betahistine acts by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as dizziness, tinnitus, and hearing loss. The drug exerts its therapeutic effect through partial agonism of histamine H1 receptors and antagonism of H3 receptors, which enhances histaminergic neurotransmission and vestibular compensation. Histigo 16 is indicated for patients experiencing episodic vertigo, imbalance, and related vestibular symptoms. It is generally well-tolerated, with adverse effects being infrequent and mild, including gastrointestinal discomfort, headache, and allergic reactions. The tablet is administered orally, with dosing tailored according to clinical response and severity of symptoms. Caution is advised in patients with pheochromocytoma or peptic ulcer disease, and it should be used under medical supervision during pregnancy and lactation. Histigo 16 provides an effective therapeutic option for improving quality of life in patients suffering from vestibular dysfunction by targeting the underlying pathophysiology of inner ear disorders. Regular follow-up is recommended to assess efficacy and monitor for potential side effects.